Kate Lathrop, MD discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2024.
The studies discussed:
- (01:28) Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy
- (07:15) Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer
- (13:02) No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial
- (19:10) A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP)
Video: https://medicaldigest.org/scientific-contents/interview:highligths-sabcs-2024
